Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SCSF1RDRD2FLT1FLT3FLT4HTR1BHTR1DHTR1FKDRKITMETOPRD1OPRK1OPRM1PDGFRAPDGFRBRET
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL11599876 | 0.97 | CA4 (0.64) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Malic Acid SCHEMBL11134436 | 0.95 | CA4 (0.61) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Malic Acid SCHEMBL95332 | 0.94 | CA4 (0.62) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Malic Acid SCHEMBL27658443 | 0.94 | CA4 (0.62) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Malic Acid SCHEMBL27637566 | 0.94 | CA4 (0.62) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Malic Acid SCHEMBL27637558 | 0.94 | CA4 (0.62) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Cadaverine Tartrate SCHEMBL25301672 | 0.93 | CA4 (0.58) | CA4SMN1; SMN2SLC22A6GABRR1LMNA | |
| Malic Acid SCHEMBL11151524 | 0.93 | SMN1; SMN2 (0.71) | CA4SMN1; SMN2SLC22A6GABRR1TDP1 | |
| Malic Acid SCHEMBL9121604 | 0.93 | SMN1; SMN2 (0.71) | CA4SMN1; SMN2SLC22A6GABRR1TDP1 | |
| Malic Acid SCHEMBL714315 | 0.92 | CA4 (0.59) | CA4SMN1; SMN2SLC22A6GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402574-B1 | PERSONAL CARE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2026-02-04 | — | — | EP | claimed |
| CN-118852854-B | Natural cellulose modified degradable oxygen-blocking breathable film and preparation method thereof | 宁波云何新材料科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118852854-A | Natural cellulose modified degradable oxygen-blocking breathable film and preparation method thereof | 宁波云何新材料科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024216362-A1 | FLAVOR MODULATION WITH MALATE SALTS AND FOOD-SAFE ACIDS | BARTEK INGREDIENTS, INC. (CA) | 2024-10-24 | — | — | WO | claimed |
| US-20240315956-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug INC | 2024-09-26 | — | — | US | claimed |
| CN-118064905-A | Electrolyte modification and electrolyte for prolonging service life of alkaline electrolyzed seawater electrode and application | 中国科学院大连化学物理研究所 | 2024-05-24 | — | — | CN | claimed |
| EP-4366732-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug Inc (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4355107-A1 | MALATE SALTS AS PH-STABILIZING AGENTS FOR HIGH-METHOXYL PECTIN-BASED GUMMY COMPOSITIONS | Bartek Ingredients Inc (CA) | 2024-04-24 | — | — | EP | claimed |
| CN-117813089-A | Process for producing cyclooxygenase-2 (COX-2) inhibitor composition | 美国纳米食品药品公司 | 2024-04-02 | — | — | CN | claimed |
| US-11839224-B2 | Partially neutralized polycarboxylic acids for acid-sanding | PURAC BIOCHEM B.V. (NL) | 2023-12-12 | — | — | US | claimed |
| EP-2475000-B1 | PROCESSING AGENT COMPOSITION FOR SEMICONDUCTOR SURFACE AND METHOD FOR PROCESSING SEMICONDUCTOR SURFACE USING SAME | WAKO PURE CHEM IND LTD (JP) | 2015-07-01 | — | — | EP | claimed |
| US-9034810-B2 | Processing agent composition for semiconductor surface and method for processing semiconductor surface using same | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-05-19 | — | — | US | claimed |
| WO-2015044394-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LOW DOSE ACTIVE PHARMACEUTICAL INGREDIENT AND PREPARATION THEREOF | SANDOZ AG (CH) | 2015-04-02 | — | — | WO | claimed |
| WO-2015028875-A2 | UNIT DOSAGE FORM COMPRISING EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITHIC TABLET COMPRISING DARUNAVIR AND RITONAVIR | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2015-03-05 | — | — | WO | claimed |
| US-20120231076-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN | RATIOPHARM GMBH (DE) | 2012-09-13 | — | — | US | claimed |
| EP-2485715-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN | Ratiopharm GmbH (DE) | 2012-08-15 | — | — | EP | claimed |
| EP-2475000-A1 | PROCESSING AGENT COMPOSITION FOR SEMICONDUCTOR SURFACE AND METHOD FOR PROCESSING SEMICONDUCTOR SURFACE USING SAME | Wako Pure Chemical Industries, Ltd. (JP) | 2012-07-11 | — | — | EP | claimed |
| US-20120157368-A1 | PROCESSING AGENT COMPOSITION FOR SEMICONDUCTOR SURFACE AND METHOD FOR PROCESSING SEMICONDUCTOR SURFACE USING SAME | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-21 | — | — | US | claimed |
| WO-2011042156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN | RATIOPHARM GMBH (DE) | 2011-04-14 | — | — | WO | claimed |
| EP-2308472-A1 | Pharmaceutical compositions comprising rivaroxaban | ratiopharm GmbH (DE) | 2011-04-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231076-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN | VKORC1, VKORC1L1, F2 | CA4 1200/4885SMN1; SMN2 1728/4885SLC22A6 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.